share_log

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K: Current report

Novo Integrated Sciences | 8-K:重大事件
美股SEC公告 ·  03/19 16:10

Moomoo AI 已提取核心訊息

Novo Integrated Sciences, Inc. reported on March 19, 2024, that it had entered into a series of agreements and waivers related to a previously issued $70 million unsecured promissory note. The note, with a 15-year term and a maturity date of April 26, 2038, was part of a securities purchase agreement with RC Consulting Group LLC, favoring SCP Tourbillion Monaco. The company faced an Event of Default under the agreement due to non-compliance with Nasdaq's minimum bid price requirements. However, an initial waiver was granted, exempting the company from non-compliance related to the minimum bid price requirement. Subsequently, RC Consulting Group LLC assigned its rights and interest in the agreement and note to RC Consulting Consortium Group LLC. On March 19, 2024, a further...Show More
Novo Integrated Sciences, Inc. reported on March 19, 2024, that it had entered into a series of agreements and waivers related to a previously issued $70 million unsecured promissory note. The note, with a 15-year term and a maturity date of April 26, 2038, was part of a securities purchase agreement with RC Consulting Group LLC, favoring SCP Tourbillion Monaco. The company faced an Event of Default under the agreement due to non-compliance with Nasdaq's minimum bid price requirements. However, an initial waiver was granted, exempting the company from non-compliance related to the minimum bid price requirement. Subsequently, RC Consulting Group LLC assigned its rights and interest in the agreement and note to RC Consulting Consortium Group LLC. On March 19, 2024, a further waiver was agreed upon, allowing the company to use the proceeds of the note for purposes other than those originally restricted, such as repaying debts to officers or investing in other entities. This waiver, known as the March 2024 Waiver, did not affect other terms of the original agreement, which remains in full force.
Novo Integrated Sciences, Inc.於2024年3月19日報告稱,它已就先前發行的7000萬美元無抵押本票簽訂了一系列協議和豁免。該票據的期限爲15年,到期日爲2038年4月26日,是與RC Consulting Group LLC簽訂的證券購買協議的一部分,該協議有利於摩納哥SCP Tourbillion LLC。由於不遵守納斯達克的最低出價要求,該公司根據協議面臨違約事件。但是,最初批准了豁免,使該公司免於違反最低出價要求的行爲。隨後,RC諮詢集團有限責任公司將其在協議和附註中的權利和利益轉讓給了RC諮詢聯盟集團有限責任公司。2024年3月19日,商定了進一步的豁免,允許公司將票據的收益用於最初限制以外的目的,例如向高管償還債務或投資其他實體。該豁免被稱爲2024年3月豁免,並未影響原始協議的其他條款,該協議仍然完全有效。
Novo Integrated Sciences, Inc.於2024年3月19日報告稱,它已就先前發行的7000萬美元無抵押本票簽訂了一系列協議和豁免。該票據的期限爲15年,到期日爲2038年4月26日,是與RC Consulting Group LLC簽訂的證券購買協議的一部分,該協議有利於摩納哥SCP Tourbillion LLC。由於不遵守納斯達克的最低出價要求,該公司根據協議面臨違約事件。但是,最初批准了豁免,使該公司免於違反最低出價要求的行爲。隨後,RC諮詢集團有限責任公司將其在協議和附註中的權利和利益轉讓給了RC諮詢聯盟集團有限責任公司。2024年3月19日,商定了進一步的豁免,允許公司將票據的收益用於最初限制以外的目的,例如向高管償還債務或投資其他實體。該豁免被稱爲2024年3月豁免,並未影響原始協議的其他條款,該協議仍然完全有效。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息